Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.
Aptamer Group has just appointed Jordan Clark as its new chief commercial officer to lead the commercial strategy and business development activities and drive the commercialisation of the Optimer technology across diagnostic and therapeutic sectors.
https://www.yorkpress.co.uk/news/19371253.aptamer-group-seeks-fresh-talent-raft-global-deals/
Dr Arron Tolley, chief executive officer of Aptamer Group, said: “Aptamer technology has great potential to offer faster and cheaper diagnostics and improve drug development to improve outcomes for a range of diseases.
Mutual Companies
Paraytec
Mark Vaux is a Mutual person - Active
(Paraytec 100% owned by Braveheart)
Kirkstall Linited
Mark Vaux is a Mutual person - Active
(Kirkstall 80% owned by Braveheart)
https://www.insidermedia.com/news/yorkshire/aptamer-group-appoints-chief-operating-officer
https://suite.endole.co.uk/insight/company/09061413-aptamer-group-limited
Yep, but beyond that, not only capable of identifying Sepsis full stop, but more importantly it will be capable of identifying which type of infection (Carl mentioned 50 most common, they are only limited by Aptamers which take only 2-4 weeks to create) thus removing the guessing game and allowing for a super quick detailed diagnosis and therefore super quick treatment, the key to treating Sepsis. It will be a device that is extremely hard to beat and certainly ground breaking on a global scale.
So once more, your device is excellent at finding those outdoors on a summer day, we can assume most will be enjoying the sunshine (like me after this post!) but the parameters have to shift to catch those indoors, and that is where LFT’s become pointless. The article states ‘false negatives’. Understand how this happens.
Nonsense, LFT’s can only see people on the streets, gardens and parks on a hot summer day. Paraytec’s device can see all the people on the streets, gardens and parks plus those who remain indoors, sitting in cars or at the shops.
Broaden your mind! Paraytec’s device does scale because one device can repeatedly do 1000’s in a day. One device can carry out daily testing for an entire school, as an example.
Rocqeut, I never mentioned false positives. One last time to try and explain, imagine you are in space looking for a specific person. You have a telescope, you can see the country, you can see the city, you can even see a network of streets, but that is your limit. Therefore you cannot find the person, now switch to Ct 35-40 and you can now see individual streets, individual houses and individual people, now you can find that person.
I feel like a parent who’s brainwashed child needs to be restrained and physically removed from the cult for their own safety and well-being.
You have NO RELIABLE evidence to ensure your device can protect the public.
It has NOT been independently scrutinised with results made public
It has NOT carried out a strong study
It has NOT been tested in the settings YOU expect it to be used
Due to its Ct value it WILL have many FALSE NEGATIVES causing harmful consequences.
It failed at Porton Down which simply backs up all the above.
When you stop talking about AVACTA on this board i will stop talking about AVACTA on this board.
Experts call for new standards for diagnostic tests to address testing problems during the COVID-19 pandemic
The Royal Statistical Society (RSS) has today published its review of the statistical evidence needed to assure the performance of future diagnostic tests, so we are better prepared for future pandemics.
The RSS Working Group on Diagnostic Tests, which is co-chaired by University of Birmingham’s Professor Jon Deeks, is calling on the Medicines and Healthcare Products Regulatory Agency (MHRA) to review and revise the national licensing process for in vitro diagnostic tests, to ensure that reliable evidence about the performance of tests is available and public safety is protected.
Present legislation does not require tests to be evaluated in the settings where they will be used, and for the evidence to be independently scrutinised and publicly available. Currently, the performance of diagnostic tests is not held to a common statistical benchmark in either the UK, US, or EU, whereas the regulatory regime for drugs and vaccines is more stringent. Covid-19 has brought this longstanding problem to the fore, as tests have come to market without evidence of their accuracy for many of the uses to which they are being applied and have been marketed with claims not supported by strong studies.
The RSS experts stress that the assessment of a test’s safety must go beyond just the safety of the device itself, to include the potentially harmful consequences of false negatives and false positives.
“Investment in well-designed studies evaluating tests in the real-world settings where they are used must become standard practice. We must learn from the mistakes made during the pandemic and put in place requirements for stronger science, better regulation and more transparency.”
https://www.birmingham.ac.uk/news/latest/2021/06/covid-diagnostic-tests-problems-new-standards.aspx
Sure
Section 15
6.
Share capital
Authorised
48,577,965 ordinary shares of 2 pence each
(30 September 2019: 33,645,000
31 March 2020: 37,915,565)
Allotted, called up and fully paid 34,698,547 ordinary shares of 2 pence each (30 September 2019: 27,082,565,
31 March 2020: 28,077,751)
https://braveheartgroup.co.uk/wp-content/uploads/2021/01/2020-09-30-BH-Interims.pdf
Even if he/she is an RMS victim, it is still an incorrect statement as they are producing masks. Had TB had more of a role on the board other than an advisory role they most likely would have purchased a machine of quality. Quality is a recurring theme with Bravehearts investments. I can see why we got out. Great product, poor inexperienced management probably not listening to the advice handed to them. IMO.
Chamberlain? Glad he is risking his own money on that one rather than BRH’s shareholders. However, there are a further 10 million shares here at BRH that can be snapped up as per half yearly report. Following the RNS stating no more funds will be required and a huge divi greater than the share price was paid out to shareholders, they can only be available for one reason.. the companies share scheme. I’m not a fan of his dealings which have affected the company he is CEO of but knowing he can swallow up a huge amount of those with a magic wand as and when.. and he will.
The next-generation coronavirus diagnostic techniques with particular emphasis on the SARS-CoV-2
The continuous evolution of new strains and viruses belong to the coronaviruses is hampering the success of many classical techniques. There are urgent needs for next generations of coronaviruses diagnostic assays that overcome these pitfalls. This new generation of diagnostic tests should be able to do simultaneous, multiplex, and high-throughput detection of various coronavirus in one reaction.
https://onlinelibrary.wiley.com/doi/10.1002/jmv.26926
I think the above paragraph highlights what we have.
I think you need to address expectations? RNS’s to date - 4th May - 26th Mar - 1st Mar and 28th Jan. it is actually happening at crazy fast speed particularly if it can knock PCR’s into touch and become the device which any LFT’s will have to rely on. The bigger sample testing pool of 250 currently being undertaken is for a reason.